


1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: William Malcolm Charles Rosenberg  
Application No.: 10/501,262  
371(c) Date: February 5, 2005  
Confirmation No.: 3832  
Title: METHODS OF DETECTING HCV GENOTYPE 1 (HCV-1) BY USING  
PRIMERS SPECIFIC FOR THE 5' NON-CODING REGION (NCR) OF THE  
HCV GENOME



Group Art Unit: 1645  
Examiner: Not yet assigned

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
8/10/2005	<i>Loretta A. Boudreau</i>
Date	Signature
LORETTA A. BOUDREAU	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application file.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☒ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
  - ☐ the explanation provided in the Specification.
  - ☐ submission of the enclosed International Search Report.
  - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
  - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Alice O. Carroll  
Alice O. Carroll  
Registration No.: 33,542  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:


August 10, 2005

PTC-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3769.1000-000APPLICATION NO.  
10/501,262SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
IN AN APPLICATIONFIRST NAMED INVENTOR  
William Malcolm Charles Rosenberg371(c) DATE:  
February 5, 2005EXAMINER  
Not yet assignedCONFIRMATION NO.  
3832GROUP  
1645

August 10, 2005

(Use several sheets if necessary)




## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AB	4,415,732	11-15-1983	Caruthers, <i>et al.</i>
	AC	4,458,066	07-03-1984	Caruthers, <i>et al.</i>
	AD	4,683,195	07-28-1987	Mullis, <i>et al.</i>
	AE	4,683,202	07-28-1987	Mullis
	AF	4,725,677	02-16-1988	Koster, <i>et al.</i>
	AG	4,973,679	11-27-1990	Caruthers, <i>et al.</i>
	AH	4,980,460	12-25-1990	Molko, <i>et al.</i>
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			
	AD3			

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED  SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 10, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3769.1000-000	APPLICATION NO. 10/501,262	
	FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		371(c) DATE: February 5, 2005
	EXAMINER Not yet assigned	CONFIRMATION NO. 3832	GROUP 1645

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	Agrawal, S. and Zamecnik, P.C., "Site Specific Functionalization of Oligonucleotides for Attaching Two Different Reporter Groups," <i>Nucleic Acids Research</i> , 18(18):5419-5423 (1990).
AV	Beaucage, S.L. and Iyer, R. P., "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach," <i>Tetrahedron</i> 48(12):2223-2311 (1992).
AW	Davis, G.L., <i>et al.</i> , "Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C," <i>The New England Journal of Medicine</i> , 339(21):1493-1499 (1998).
AX	Gut, M., <i>et al.</i> , "One-tube Fluorogenic Reverse Transcription-polymerase Chain Reaction for the Quantitation of Feline Coronaviruses," <i>Journal of Virological Methods</i> , 77:37-46 (1999).
AY	Holland, P.M., <i>et al.</i> , "Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5'→3' Exonuclease Activity of <i>Thermus aquaticus</i> DNA Polymerase," <i>Proc. Natl. Acad. Sci. USA</i> , 88:7276-7280 (1991).
AZ	Innis, M.A. and Gelfand, D.H., "Optimization of PCRs" in <i>PCR Protocols: A Guide to Methods and Applications</i> , eds. (NY: Academic Press, Inc.), pp. 3-28 (1990).
AR2	Martell, M., <i>et al.</i> , "High-Throughput Real-Time Reverse Transcription-PCR Quantitation of Hepatitis C Virus RNA," <i>Journal of Clinical Microbiology</i> , 37(2):327-332 (1999).
AS2	Ozaki, H. and McLaughlin, L.W., "The Estimation of Distances Between Specific Backbone-labeled Sites in DNA Using Fluorescence Resonance Energy Transfer," <i>Nucleic Acids Research</i> , 20(19):5205-5214 (1992).
AT2	Poynard, T., <i>et al.</i> , "Randomised Trial of Interferon α2b Plus Ribavirin for 48 Weeks or for 24 Weeks Versus Interferon α2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus," <i>The Lancet</i> , 352:1426-1432 (1998).
AU2	Preudhomme, C., <i>et al.</i> , "Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a 'Real Time' Quantitative RT-PCR Assay," <i>Leukemia</i> , 13:957-964 (1999).
AV2	Sambrook, <i>et al.</i> , <i>Molecular Cloning</i> , Second Edition, (Cold Spring Harbor Laboratory, New York), (1989), Chapter 18, pp. 146-152, Chapter 6, pp. 6.1-6.62, Chapter 7, pp. 7.1-7.87, Chapter 14, pp. 14.1-14.35.

EXAMINER

DATE CONSIDERED

APPLICATION NO.  
10/501,262

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
IN AN APPLICATION**

**August 10, 2005**

(Use several sheets if necessary)

FIRST NAMED INVENTOR

William Malcolm Charles Rosenberg

371(c) DATE:

February 5, 2005

EXAMINER

Not yet assigned

CONFIRMATION NO.

3832

GROUP

1645

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

[illegible]

EXAMINER

DATE CONSIDERED